Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T. Hidaka M, et al. Among authors: ota s. Jpn J Clin Oncol. 2024 Feb 7;54(2):153-159. doi: 10.1093/jjco/hyad156. Jpn J Clin Oncol. 2024. PMID: 37986553 Free PMC article.
Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.
Qi J, Choi I, Ota S, Ichikawa S, Fujishima N, Iida H, Sugiura I, Sugiura K, Murata Y, Inoue H, Ohwada S, Wang J. Qi J, et al. Among authors: ota s. Clin Pharmacol Drug Dev. 2024 May;13(5):560-571. doi: 10.1002/cpdd.1353. Epub 2024 Jan 29. Clin Pharmacol Drug Dev. 2024. PMID: 38284515 Clinical Trial.
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Among authors: ota s. Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26. Int J Hematol. 2024. PMID: 38532078 Free PMC article. Clinical Trial.
FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
Matsukawa T, Onozawa M, Kondo T, Kanaya M, Hidaka D, Ota S, Mori A, Shigematsu A, Miyagishima T, Kakinoki Y, Hashiguchi J, Yamamoto S, Yamamoto M, Wakasa K, Takahata M, Ishihara T, Haseyama Y, Fujimi A, Igarashi T, Sarashina T, Iyama S, Kobayashi R, Sakai H, Fujimoto K, Inamura J, Kanisawa Y, Hirabayashi S, Endo T, Hashimoto D, Teshima T. Matsukawa T, et al. Among authors: ota s. Ann Hematol. 2024 Dec;103(12):5333-5340. doi: 10.1007/s00277-024-06125-9. Epub 2024 Nov 30. Ann Hematol. 2024. PMID: 39614924
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.
Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y. Nakagawa N, et al. Among authors: ota s. Ann Hematol. 2024 Jan;103(1):307-320. doi: 10.1007/s00277-023-05527-5. Epub 2023 Nov 8. Ann Hematol. 2024. PMID: 37940714
1,648 results